Biogen Inc
Company Profile
Business description
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Contact
225 Binney Street
CambridgeMA02142
USAT: +1 617 679-2000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
7,500
Stocks News & Analysis
stocks
Nvidia: Hugging Face acquisition both a wise offensive and defensive move
stocks
Anthropic’s IPO will be huge—and risky. Here are the challenges investors should watch
stocks
Chart of the Week: China demand for copper falls amidst record rally
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,196.00 | 54.60 | -0.59% |
| CAC 40 | 8,286.40 | 5.77 | 0.07% |
| DAX 40 | 26,003.32 | 163.99 | 0.63% |
| Dow JONES (US) | 53,686.11 | 624.16 | 1.18% |
| FTSE 100 | 10,831.52 | 75.07 | 0.70% |
| HKSE | 25,714.06 | 500.75 | 1.99% |
| NASDAQ | 26,584.06 | 366.23 | 1.40% |
| Nikkei 225 | 64,980.87 | 766.39 | 1.19% |
| NZX 50 Index | 13,974.18 | 128.00 | 0.92% |
| S&P 500 | 7,747.71 | 81.11 | 1.06% |
| S&P/ASX 200 | 9,005.90 | 64.30 | -0.71% |
| SSE Composite Index | 3,939.77 | 2.31 | -0.06% |